FDA Panel Votes Against Deramiocel

Company Capricor Therapeutics Event Type Regulatory (Advisory Committee Vote) Modality Allogeneic cardiosphere-derived cell therapy Asset Deramiocel (BLA 125842) Target Inflammation, fibrosis, and tissue repair via paracrine signaling Disease Area Cardiomyopathy associated with Duchenne muscular dystrophy Summary FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee voted…